Cervical Cancer Could Be the First Cancer Eliminated. So Who Gets the Vaccine?
14 July 2026
In a handful of countries, something quietly historic is happening. The first generation of girls offered the HPV vaccine has now reached adulthood, giving rise to a generation in which cervical cancer is beginning to disappear. Norway has recorded no HPV-caused cervical cancer among the under-25s who were the first to be vaccinated. Sweden is on course to become the first country to cross the elimination threshold. England's programme has almost erased the disease in women born since the mid-1990s. For the first time in the history of oncology, we are watching a cancer being stopped at its source.
The World Health Organization (WHO) has recognised what once sounded impossible: cervical cancer could be the first cancer ever to be eliminated. Nearly all of it is caused by a single virus, and we have a vaccine that stops that virus. Block the infection, and you block the cancer years before it could begin.
And yet. In 2022, only about one in five girls worldwide had received a first dose of that vaccine. A cancer we know how to prevent still kills around 350,000 women every year, one roughly every two minutes, and 94% of those deaths fall in low- and middle-income countries. The science is not the bottleneck. The science already exists. The bottleneck is who the science reaches.
That gap is the real subject of this article, because cervical cancer is no longer the only place the word "vaccine" appears in oncology. There are now three kinds of cancer vaccines at three very different stages of maturity, and the same underlying question, the distance between what is possible and who benefits, shapes all three.
This article explores:
Why cervical cancer is poised to become the first cancer humanity eliminates, and what "elimination" actually means.
How a single virus writes a cancer at the molecular level, and how the vaccine interrupts the story before it starts.
Why a preventable cancer still kills hundreds of thousands of women a year, and why even wealthy countries are now sliding backwards.
How the new mRNA neoantigen vaccines fight cancer by a completely different logic, and why their bespoke design makes them powerful but hard to scale.
Whether universal, off-the-shelf cancer vaccines could close the access gap the field is opening, or simply widen it.
What researchers, communicators, industry and funders would each need to do to make cancer vaccines reach the people who need them most.
One virus, almost every case
Most cancers are a tangle of genetics, environment, age and luck. Cervical cancer is the rare exception. Around 99% of cases trace back to persistent infection with high-risk strains of human papillomavirus. That single-cause structure is what makes elimination thinkable at all: there is one thing to block, and blocking it protects even the unvaccinated by starving the virus of hosts.
The tools have existed for years. A preventive vaccine, introduced in 2006 and broadened since. Screening that can now be done with a high-performance HPV test, sometimes from a self-collected sample. Treatment for the precancerous lesions caught early. The WHO defines elimination as fewer than four cases per 100,000 women per year, and in 2020 all 194 member states adopted a global strategy built on three targets for 2030: 90% of girls fully vaccinated by age 15, 70% of women screened with a high-performance test, and 90% of those with disease treated.
Some countries are within sight of the line. Australia is on track for the early 2030s. England has pledged 2040. Bhutan became the first low- or middle-income country to hit all three targets, in 2023. The direction of travel is unmistakable, and it points somewhere no cancer has gone before.
How HPV turns a cell cancerous
To see why prevention is so much more powerful than any treatment downstream, it helps to look at what the virus actually does.
High-risk HPV, chiefly types 16 and 18, which together cause around 70% of cervical cancers, carries two small genes that do the damage: E6 and E7. Neither is subtle. The E6 protein recruits a cellular enzyme called E6-associated protein and uses it to tag p53, the cell's central tumour suppressor, for destruction. With p53 degraded, the cell loses its ability to pause, repair or self-destruct when something goes wrong. In parallel, E7 binds the retinoblastoma protein and prises apart the Rb-E2F complex that normally holds the cell cycle in check. One protein removes the brakes on damage; the other jams the accelerator on division. Together they immortalise the infected cell and start it on the road to malignancy.
The vaccine does none of this repair work. It never has to. It prevents the infection that sets the whole sequence in motion, which is precisely why a preventive vaccine can protect a population at a fraction of the cost and complexity of treating the cancers it forestalls. Hold that thought, because the treatment vaccines later in this story have to do their work after the machinery is already running.
One in five
The success, though, has a clear limit. The vaccine works, spectacularly, yet it does not reach most of the girls in the world. In 2022, global first-dose coverage sat at roughly one in five. In many low- and middle-income countries, fewer than 5% of women are ever screened. The result is stark: 94% of cervical cancer deaths occur in those countries, in women whose cancers were, in the most literal sense, preventable.
"Equity must be at the heart of our elimination strategy," the WHO's Director-General, Dr Tedros Adhanom Ghebreyesus, told health ministers in 2025. "Together, we can consign cervical cancer to the history books."
And the machinery to do it is now assembling at scale. In November 2025, Gavi, the Vaccine Alliance announced that it had protected an estimated 86 million girls with the HPV vaccine, most of them in the previous three years, and helped prevent more than a million future cervical cancer deaths. Coverage in Africa has climbed from 28% in 2022 to 44% by the end of 2024, overtaking Europe. A single-dose schedule, now adopted by dozens of countries, stretches supply further still. For the first time, vaccine supply is no longer the main obstacle. Gavi's next goal is to reach 120 million more girls by 2030, though that depends on the alliance being fully funded for the years ahead.
If supply is no longer the barrier, delivery, screening and trust are. And progress is neither automatic nor irreversible, with the clearest warning coming from a wealthy country, not a poor one. In Canada, cervical cancer is now the fastest-increasing cancer, rising 3.7% a year since 2015, the first sustained increase since 1984, as vaccination and screening slip and confidence erodes. Elimination is not achieved once and then kept automatically. It depends on sustained vaccination and screening, and that coverage can fall.
A personalised cancer vaccine
While the HPV vaccine works to stop cancer from ever starting, a newer class of vaccine has begun to treat cancers that already exist, and it works by an entirely different logic.
These are personalised neoantigen vaccines. The idea is elegant. When a tumour is removed, it is sequenced, and its unique mutations, the errors that exist only in the cancer and nowhere else in the body, are identified. A vaccine, usually mRNA wrapped in a lipid nanoparticle, is then built to order to teach the immune system to recognise those specific mutations and hunt the cancer cells that carry them.
The early results are striking, and they come from some of the hardest cancers we treat. In pancreatic ductal adenocarcinoma, a disease that kills the large majority of patients within five years, an individualised mRNA vaccine called autogene cevumeran produced immune responses in half of the patients in a small Phase 1 trial. Years later, the responders are still surviving: at the latest follow-up, seven of the eight patients who responded were alive four to six years after treatment, and the vaccine-induced T cells showed an estimated lifespan measured in years, not weeks. "
“Autogene cevumeran can induce CD8-positive T cells with significant longevity, substantial magnitude and durable function," reported the study's lead, Dr Vinod Balachandran of Memorial Sloan Kettering.
In high-risk melanoma, the personalised vaccine intismeran autogene, given alongside the immunotherapy pembrolizumab, cut the risk of recurrence or death by 49% at five years compared with pembrolizumab alone, and reduced the risk of the cancer spreading to distant organs by 59%. A definitive Phase 3 trial is now under way.
But look closely at how these vaccines are made, and the catch appears. Each one is bespoke, sequenced and manufactured for a single patient over a period of weeks. That is precision of the highest order, and it is close to the opposite of scalable. The HPV vaccine reaches millions with one product. A neoantigen vaccine reaches one person with one product. If the future of cancer treatment is personalised, it is not a model that easily widens access.
The universal hope
Which brings us to the newest and least certain part of the story, and the one that could resolve the tension the personalised vaccines create.
A third approach does not target any specific tumour at all. Instead of teaching the immune system to recognise a particular set of mutations, it simply switches the whole system on, as though it were fighting an infection, and lets an accompanying immunotherapy do the aiming. In one line of work, a research team found that a generalised mRNA vaccine, built much like the COVID-19 vaccines but not aimed at any tumour, shrank and in some cases eliminated treatment-resistant tumours in mice when paired with a checkpoint inhibitor. The vaccine worked, in the words of one of its authors, by provoking "a very strong anticancer reaction" without being designed against the cancer at all. A parallel effort is pursuing off-the-shelf vaccines against mutations that many patients share, such as those in the KRAS gene, which could be manufactured in advance rather than built to order.
This work is early. Much of it is still in animal models or the first phases of human testing, and none of it is close to the clinic. But its promise is exactly the thing the personalised vaccines lack: something that could be made once and given to many. An off-the-shelf cancer vaccine could, in principle, democratise treatment the way the HPV vaccine could democratise prevention. Or, like so many advances before it, it could arrive first and fastest in the places where access is already best. The biology will decide whether it works. Who it reaches will come down to cost, policy and delivery, not to the science.
What happens next
The vaccine spectrum, from prevention to personalisation to a possible universal option, is a map of extraordinary scientific progress. It is also, at every stage, a test of distribution. Different actors hold different parts of the answer.
For researchers, the central question is no longer only whether cancer vaccines work, but whether they can be built to scale. The contest between personalised and off-the-shelf designs is, at heart, a contest about access.
For science communicators, the Canadian warning matters as much as any trial result. A vaccine that is not trusted is a vaccine that is not taken, and eroding confidence can undo decades of progress as surely as any supply shortage. Protecting elimination means protecting the case for it.
For industry and policymakers, prevention remains the highest-return intervention in all of oncology, and one of the most underfunded relative to the therapeutic frontier. The money and attention flow towards the dazzling and the personalised. The largest number of lives sits with the cheap and the preventable.
For global health funders, the window is now. Vaccine supply is, for the first time, not the binding constraint. Delivery, screening and treatment access are. The tools to eliminate a cancer already exist. Whether they reach the women who need them is a choice, not a scientific problem.
The rule or the exception
There is a version of the next decade in which we look back on this moment as the beginning of the end of cervical cancer, and the beginning of a broader era in which vaccines prevent and treat cancers we once thought untouchable. The science is delivering its part of that story faster than almost anyone predicted.
But the lesson that runs the length of the vaccine spectrum is the same one that runs through the history of every powerful medicine: the discovery is the easy part. Across prevention, personalisation and the universal frontier, the science is not the bottleneck. The distribution is. We are about to prove, with cervical cancer, that a cancer can be erased. The question that remains is whether it becomes the rule, or stays the exception.
References
World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva: WHO; 2020.
Ghebreyesus TA. For the first time, the elimination of a cancer is within our reach. WHO commentary; 18 November 2024. who.int
World Health Organization (Western Pacific) / UICC. Global leaders unite to accelerate cervical cancer elimination efforts. 2nd Global Cervical Cancer Elimination Forum, Bali; 19 June 2025.
International Agency for Research on Cancer. Cervical cancer incidence and mortality, GLOBOCAN 2022. Lyon: IARC/WHO.
Cervical cancer elimination cohort data (no HPV-caused cervical cancer in first vaccinated cohorts; Sweden and Australia elimination trajectories), as reported by WHO/UICC and national cancer registries, 2024–2025.
Canadian Cancer Statistics: rising cervical cancer incidence (+3.7% per year since 2015), Canadian Cancer Society, 2024.
Pal A, Kundu R. Human papillomavirus E6 and E7: the cervical cancer hallmarks and targets for therapy. Front Microbiol. 2019;10:3116. doi:10.3389/fmicb.2019.03116
Rojas LA, Sethna Z, Soares KC, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618:144–150. doi:10.1038/s41586-023-06063-y
Sethna Z, Guasp P, Reiche C, et al. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Nature. 2025;639:1042–1051. doi:10.1038/s41586-024-08508-4
Memorial Sloan Kettering Cancer Center. Autogene cevumeran six-year follow-up (7 of 8 responders alive 4–6 years). Presented at AACR Annual Meeting 2026.
Merck / Moderna. KEYNOTE-942 (NCT03897881): five-year data for intismeran autogene (mRNA-4157) plus pembrolizumab in resected high-risk melanoma. Presented at ASCO Annual Meeting 2026.
Sayour EJ, Lin SH, et al. SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature.2025;647:488–497. doi:10.1038/s41586-025-09655-y
Off-the-shelf shared-neoantigen (KRAS) mRNA vaccine studies; representative early-phase work in KRAS-mutant solid tumours, 2024–2026.
